Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCS1477 + olaparib
- Development stage
- Unknown
- Lead developer
- CellCentric
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**CCS1477 + olaparib** is an investigational combination therapy consisting of CCS1477 and olaparib. CCS1477 is a small molecule inhibitor that targets the bromodomains of p300/CBP, thereby down-regulating androgen receptor (AR) and MYC signaling, which are critical pathways in several hormone-driven cancers, including prostate and breast cancer. Olaparib is an approved small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes (PARP1, PARP2), exploiting defective DNA repair mechanisms (such as BRCA mutations) in cancer cells to selectively induce tumor cell death. The combination aims to enhance anti-tumor effects by suppressing both AR/MYC signaling (via CCS1477) and DNA repair (via olaparib), especially in prostate cancer (mCRPC) and metastatic breast cancer, potentially overcoming or delaying resistance to either agent alone[1][2].
- Brand names
- Lynparza (for olaparib)
02
Targets
CREBBP BD (Creb-binding protein bromodomain)MYC (MYC proto-oncogene protein)EP300 (Histone acetyltransferase p300)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on CCS1477 + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCS1477 + olaparib.